Loophole in Patent Law Brings ‘Miracle Drug’ to Patients Who Can’t Afford It
Beximco Pharma has initiated the supply of a low-cost cystic fibrosis medication to patients across six countries following a patent law loophole.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Beximco Pharma has begun distributing a generic version of a cystic fibrosis treatment, branded as TRIKO, to patients in six countries. This initiative provides a lower-cost alternative for individuals unable to access existing, higher-priced therapies. The distribution is characterized as a response to specific gaps within current patent law regulations.
Coverage from The New York Times, TipRanks, Newagebd.net, The Business Standard, and daily-sun.com highlights the drug's affordability and the legal mechanism enabling its release. Reports emphasize that the first patients have already received the therapy, marking the start of the supply program. Future developments will depend on the continued availability of the medication and any potential regulatory or legal responses regarding the use of the patent loophole.
Coverage does not yet specify which countries are included in the distribution or the long-term impact on global access to the therapy.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 106d ago.
Quick answers
What is the name of the new medication?
The medication is referred to as TRIKO.
How is Beximco Pharma able to offer this drug at a lower cost?
Coverage indicates the company is utilizing a loophole in patent law.
Which countries are receiving the medicine?
Coverage confirms that patients from six countries are included, though specific names of the countries have not been released.
Coverage (6)
- Beximco Pharma hands over low-cost generic cystic fibrosis drug to patients The Business Standard · 106d ago
- Beximco Pharma hands over affordable CF medicines to patients from six countries daily-sun.com · 106d ago
- Beximco Pharma starts supplying low-cost cystic fibrosis medicine Newagebd.net · 106d ago
- affordable medicine The Business Standard · 106d ago
- Beximco launches cut‑price cystic fibrosis therapy as first patients receive TRIKO TipRanks · 106d ago
- Loophole in Patent Law Brings ‘Miracle Drug’ to Patients Who Can’t Afford It The New York Times · 106d ago
Topics
Related trends
Apple must pay Masimo an extra $184M for Apple Watch patent infringement
Apple faces a significantly increased payout to Masimo after interest added $184 million to an existing $634 million patent infringement judgment.
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New weight-loss drug could give you a ‘flatter stomach’ in mere weeks
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
America Wants to Make More Generic Drugs. India Shows Why That’s Hard.
The U.S. government is pushing to reshore the production of essential medicines amid new tariffs, while India's dominant role complicates these goals.
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.